• E. coli Uracil-DNA Glycosylase (UDG) Guide

  2026-08-31

  E. coli Uracil-DNA Glycosylase (UDG), SKU K1107, removes uracil residues from single- and double-stranded DNA and can support PCR product contamination elimination workflows. It is intended for research use with DNA substrates, not RNA, oligonucleotides shorter than six bases, or diagnostic and medical applications.

• Tomivosertib Suppresses Human DRG Ectopic Activity

  2026-08-30

  The reference study provides direct human-neuron evidence that MNK inhibition with tomivosertib rapidly and reversibly suppresses spontaneous activity in sensory neurons obtained from patients with radiculopathy. Its combination of clinically anchored human tissue, electrophysiology, and rapid eIF4E phosphorylation measurements strengthens the case for MNK signaling as a translational target in neuropathic pain.

• p21 mRNA–LNP Delivery for Bladder Cancer

  2026-08-29

  The reference study develops an intravesical, nonviral strategy for restoring the tumor suppressor p21 in bladder cancer using chemically modified p21 mRNA encapsulated in lipid nanoparticles. Its findings connect localized protein expression with cell-cycle suppression, DNA-damage signaling, apoptosis, and reduced tumor growth in an orthotopic mouse model, while also highlighting the translational questions that remain before clinical evaluation.

• Deep Learning for iPSC-CM Cardiotoxicity Screening

  2026-08-29

  Grafton and colleagues combined human induced pluripotent stem cell-derived cardiomyocytes, high-content imaging, and deep learning to identify cardiotoxic phenotypes across compound libraries. The study supports an early, target-agnostic strategy for prioritizing toxicology follow-up during drug discovery while highlighting the need for orthogonal validation and careful model transfer.

• Rotigotine: A Translational Strategy for PD Research

  2026-08-28

  A mechanistic and strategic guide to using Rotigotine as a dopamine D2/D3 receptor agonist across Parkinson’s disease, neuroprotection, depression, and translational assay development.

• Telatinib (BAY 57-9352) Research Workflows

  2026-08-28

  Build mechanism-aware angiogenesis, invasion, and combination-treatment assays with Telatinib rather than relying on viability alone. This workflow translates HER2–VEGFR2 findings in triple-negative breast cancer into practical dosing, endpoint selection, and troubleshooting decisions.

• Oligo (dT) 25 Beads for Mechanistic RNA Studies

  2026-08-27

  Oligo (dT) 25 Beads enable selective polyA-tail mRNA capture for clean, interpretable gene-expression studies. This guide connects magnetic mRNA purification with the PLPP1-centered cisplatin-resistance findings reported in a lung-cancer preprint, emphasizing assay design, controls, and limitations.

• 7-dehydro Cholesterol as a Causal Probe

  2026-08-27

  7-dehydro Cholesterol is both a DHCR7 substrate and a photoreactive, oxidation-sensitive sterol. This article presents a causal experimental framework for connecting sterol measurements with vitamin D3 synthesis research, skin model research, and antiviral phenotypes.

• Thymoquinone Protects Against Doxorubicin Cardiotoxicity

  2026-08-26

  A 2025 mouse study reports that Thymoquinone reduces doxorubicin-associated cardiac injury while restoring antioxidant and ferroptosis-related responses. Its multimodal design links functional cardiac measurements with redox biomarkers, pathway proteins, immunohistochemistry, and mitochondrial ultrastructure, providing a useful preclinical framework for studying chemotherapy-induced cardiotoxicity.

• AIBP-LRP2 Control of Collateral Vessel Formation

  2026-08-26

  Zhu et al. identify an AIBP-LRP2-HDL-miR-223 signaling axis that suppresses CXCR4+ stemlike capillary endothelial cells and limits collateral circulation after ischemia. The work links lipid handling to endothelial state transitions and suggests that restoring CXCR4 activity could improve revascularization, although translation beyond experimental ischemia requires further validation.

• Zosuquidar (LY335979) in MDR Assays

  2026-08-25

  Zosuquidar (LY335979) 3HCl provides a selective way to test whether P-glycoprotein efflux is driving chemotherapy failure. This guide connects MDR reversal assays with intracellular drug measurements, transporter models, and practical troubleshooting for leukemia, lymphoma, and solid-tumor research.

• Cefazedone (Refosporen): Applied Lab Workflows

  2026-08-25

  Cefazedone (Refosporen) supports structured broth-microdilution studies spanning Gram-positive and Gram-negative bacterial infections. This guide connects reproducible MIC testing with β-lactamase-aware assay design, formulation control, and cautious PK/PD translation.

• Autophagy–Metastasis Signature in Colorectal Cancer

  2026-08-24

  Bai et al. integrated bulk and single-cell transcriptomic data to develop a six-gene colorectal cancer risk signature linking autophagy, liver metastasis, immune dysfunction, and treatment response. The study offers a useful framework for interpreting prognostic heterogeneity, while its retrospective and computational design means that the signature still requires prospective and mechanistic validation.

• From ARL4C Biology to Actionable S-Phase Data

  2026-08-23

  A translational framework for using direct EdU DNA-synthesis measurements to validate ARL4C-driven fibroblast-like synoviocyte proliferation, strengthen rheumatoid arthritis pharmacodynamic studies, and connect molecular findings with actionable experimental decisions.

• Angiotensin I/II (1-5) Workflow Guide

  2026-08-22

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research involving blood pressure and aldosterone-related readouts. This guide addresses solvent handling, storage, QC, and interpretation when no directly matched paper evidence is available; it should not substitute for angiotensin I, angiotensin II, or unrelated peptide-signaling controls.

449 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page